Hygieia pitches biosynthesized urolithin A to wholesale buyers

Hygieia is promoting its biosynthesis-based Urolithin A powder as a higher-consistency alternative to plant extraction for nutraceutical and anti-aging brands. The company says its 99% powder, logistics options, and OEM/ODM services are aimed at formulators seeking scalable supply and regulatory-ready ingredients.

Why it matters: - Wholesale buyers in cellular health are choosing between plant extraction and enzyme-driven biosynthesis for Urolithin A supply. - The shift affects purity, batch consistency, cost at scale, and exposure to agricultural supply risks. - Urolithin A is used in longevity, muscle health, and other anti-aging formulations.

What happened: - Hygieia, legally registered as Shenzhen Hygieia Biotech Co., Ltd., is positioning itself as a supplier of Urolithin A 99% powder for global formulators and brand owners. - The company says its production uses proprietary Zymevolver strain construction technology and an enzyme engineering evolution platform. - Hygieia also says it offers bulk ingredients including Ca-AKG, NMN, PQQ, DCI, and L-5-MTHF. - The company lists its enterprise website as More information.

The details: - Urolithin A is identified as a natural gut-microbiome metabolite with CAS Registry Number 1143-70-0. - The compound is described as 3,8-Dihydroxy-6H-dibenzo[b,d]pyran-6-one, with molecular formula C13H8O4 and molecular weight 228.20 g/mol. - High-purity Urolithin A is described as an off-white to pale yellow crystalline powder with low aqueous solubility. - Urolithin A is not naturally present in food and is produced in the gut from ellagitannins and ellagic acid found in pomegranates, strawberries, walnuts, raspberries, and apple peels. - The release says less than 40% of the global population has the gut microbiome needed to efficiently convert those precursors into therapeutic amounts of Urolithin A. - The molecule is described as supporting mitophagy, mitochondrial biogenesis, skeletal muscle health, and neuroprotection. - The FDA reviewed Urolithin A under GRAS notification GRN No. 791 for use in functional food and dietary supplement applications. - Standard human clinical trials are described as showing good tolerability and no significant adverse effects at recommended doses. - Typical daily supplement dosages are listed at 250 mg to 1,000 mg per day. - Plant extraction is described as relying on pomegranate husks or walnut shells, followed by acid hydrolysis or chemical conversion. - The release says extraction can face seasonal raw material swings, lower yields, inconsistent batches, and possible pesticide or heavy metal residue. - Biosynthetic manufacturing is described as using enzyme engineering and microbial fermentation to produce high-purity Urolithin A. - The biosynthesis path is said to deliver 99%+ purity, lower unit costs at scale, and fewer supply chain risks. - Hygieia says its manufacturing supports flexible packaging, including 1kg aluminum foil bags and 25kg industrial drums. - The company says it can handle worldwide logistics by air freight, sea shipping, FedEx, and UPS. - Hygieia says it also provides strain development, formula optimization, custom formula design, private label contract manufacturing, and OEM/ODM finished product manufacturing.

Between the lines: - The pitch reflects a broader move in supplement sourcing away from agricultural inputs and toward controlled biotech production. - The emphasis on 99% purity, logistics, and turnkey services suggests Hygieia is targeting formulators that want fewer suppliers and faster commercialization. - The release also tries to frame biosynthesis as both a quality upgrade and a supply chain hedge.

What's next: - Buyers evaluating Urolithin A ingredients are likely to compare biosynthetic suppliers against extraction-based suppliers on purity, consistency, compliance, and price. - Hygieia is directing prospective customers to its website for technical documentation, specifications, and OEM/ODM inquiries.

The bottom line: - Hygieia is betting that biosynthesized Urolithin A will win wholesale buyers who want steadier supply and pharmaceutical-style consistency over botanical extraction.